Predict your next investment

Venture Capital
noeticfund.com

See what CB Insights has to offer

Investments

6

Funds

2

About Noetic Fund

Noetic Fund is a venture fund launched by Grey House Partners GP Inc. to invest in emerging and early-stage psychedelic-based wellness, therapeutic and pharmaceutical companies around the globe.

Noetic Fund Headquarter Location

100 Broadview Ave Ste 300

Toronto, Ontario, M4M 3H3,

Canada

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Noetic Fund News

CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development

Sep 10, 2021

CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development   ISSAQUAH, Wash., Sept. 08, 2021 (GLOBE NEWSWIRE) —  CaaMTech , Inc., a leading psychedelic drug discovery company, has today announced the completion of a $22 million Series A financing round, led by Noetic Fund. The oversubscribed round of funding will be deployed to support CaaMTech’s industry-leading cross-disciplinary science program, expand the company’s leadership team, and advance its foremost drug development candidates into human trials. “This Series A investment further substantiates our hypothesis that the future of the psychedelics industry depends on the strength of its foundation,” said CaaMTech founder and CEO,  Dr. Andrew Chadeayne . “Now that we have built that foundation, we are grateful to partner with Noetic for the next steps. Their industry leadership and experienced team make Noetic the optimal partner to help shepherd these drugs to the patients who need them most.”   CaaMTech was founded in 2017 to fill the unmet need for pure, well-characterized psychedelic drugs. Since then, the company has produced an extensive library of novel, analytically pure compounds that are nearing advancement into human trials. “CaaMTech’s extensive patent library, scientific and research-laden focus, coupled with their impressive leadership team and an unwavering commitment to pursuing drug development within the psychedelic industry make them one of the most formidable companies in this space,” said Sa’ad Shah, co-founder and managing partner of the Noetic Fund. “We could not be more excited about our support and investment in CaaMTech.”   CaaMTech has led the psychedelics industry in fundamental research, publishing tens of peer-reviewed scientific research publications. Through collaborations with the NIH’s Designer Drug Research Unit at the National Institute on Drug Abuse, the University of Massachusetts Dartmouth, and The Leibniz Institute for Natural Product Research, CaaMTech has built a cross-disciplinary team of world-class scientists, providing diverse subject matter expertise and a shared goal to advance the state of the art of the psychedelic industry. The successful completion of Series A funding will allow CaaMTech to continue its dedication to fundamental scientific research through continued academic collaboration while advancing individual drug candidates toward the clinic. About CaaMTech CaaMTech  is the foremost drug discovery and lead optimization company focused on engineering psychedelic drugs that meet the standards of modern medicine. CaaMTech is improving the health and happiness of humankind by creating and optimizing psychedelic compounds and formulations through rigorous science and continuous innovation. About Noetic Noetic is a group of venture funds launched by Grey House Partners GP Inc. to invest in emerging and early-stage psychedelic and CNS companies, addressing global unmet healthcare needs such as mental health conditions, substance use disorders, and distinct inflammatory-related ailments. Noetic has built a team with the deep domain expertise required to appraise opportunities in this nascent sector: from neuroscience and pharmacology through to regulatory pathways and health economics. The firm is committed to scaling the disruptive potential of psychedelics in a responsible manner, with a core mission of supporting the development of innovative technologies that help define a healthy future for people and the planet. This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information. About Ryan Allway Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies. Search CannabisFN About CFN Media Group CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com. Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/ .

Noetic Fund Investments

6 Investments

Noetic Fund has made 6 investments. Their latest investment was in Delix Therapeutics as part of their Series A on September 9, 2021.

CBI Logo

Noetic Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/27/2021

Series A

Delix Therapeutics

$70M

Yes

5

9/9/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

5/21/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

5/6/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

12/18/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/27/2021

9/9/2021

5/21/2021

5/6/2021

12/18/2020

Round

Series A

Series A

Seed VC

Series A

Series A

Company

Delix Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$70M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

10

10

10

10

Noetic Fund Fund History

2 Fund Histories

Noetic Fund has 2 funds, including Noetic Psychedelic Fund I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/8/2020

Noetic Psychedelic Fund I

$0.2M

1

11/17/2020

Noetic Psychedelic Fund

Subscribe to see more

$99M

10

Closing Date

12/8/2020

11/17/2020

Fund

Noetic Psychedelic Fund I

Noetic Psychedelic Fund

Fund Type

Subscribe to see more

Status

Amount

$0.2M

$99M

Sources

1

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.